Medical News

RSS

Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented

Lexicon Pharmaceuticals, Inc., announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders."

23 Nov 2009

AMD LASERS announces new collaboration to continue its dental education

AMD LASERS announced this week that it continues with an ongoing commitment to dental education by partnering with prestigious industry-leader Dr. Larry Rosenthal and Aesthetic Advantage. Picasso, by AMD LASERS, will be the exclusive soft tissue diode laser used during all international educational activities, which are targeted to the top 2% of dentists.

From AMD Lasers 23 Nov 2009

Acucela to present data on its ACU-4429 visual cycle modulator for dry AMD

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that data for the company’s novel visual cycle modulator, ACU-4429, a potential oral treatment for dry age-related macular degeneration (dry AMD), will be featured at the 8th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) being held in Rome, Italy from December 3 to 6, 2009.

23 Nov 2009

Masimo announces the renewal of multi-year agreement by Advocate Health Care

Masimo, the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Advocate Health Care--Illinois' largest health care provider--has renewed its multi-year, system-wide contract for Masimo SET pulse oximetry technology.

23 Nov 2009

Texas Court dismisses all claims against Merck in VIOXX-related lawsuit

Merck said today that Travis County, Texas District Court Judge Scott H. Jenkins granted Merck's motion for summary judgment, dismissing all claims in a VIOXX-related lawsuit filed on behalf of the State of Texas.

23 Nov 2009

Asterand extends its collaboration agreement with Bristol-Myers Squibb

Asterand plc, a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years.

23 Nov 2009

AdnaTest BreastCancer Select & Detect kit now available in the Czech Republic and Slovakia

OncoVista Innovative Therapies, Inc., reported that the AdnaTest BreastCancer Select & Detect kit, manufactured by AdnaGen AG (Langenhagen, Germany), is now available for research as well as for pay-out-of-pocket patients in the Czech Republic and Slovakia.

23 Nov 2009

Zynx Health partners with Healthcare Solutions Division of Keane for EHR integration

Zynx Health, the market leader in providing evidence-based and experience-based clinical decision support solutions, today announced its partnership with the Healthcare Solutions Division of Keane, Inc., allowing the integration of Zynx Health solutions with Keane’s OptimumTM electronic health records (EHR) system.

23 Nov 2009

Isis Pharmaceuticals CEO's letter to shareholders

I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the most successful moments in our history. We are truly at the end of the beginning of creating a unique company with a novel drug discovery platform, which we believe addresses many of the issues haunting the pharmaceutical industry.

23 Nov 2009

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, today announced positive interim results from a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) plinabulin (NPI-2358) in combination with standard chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC).

23 Nov 2009

Nevada Cancer Institute selects Sprint as its wireless communications provider at its new Las Vegas facility

Nevada Cancer Institute has selected Sprint as its wireless communications provider of choice at its new, state-of-the-art facility near Las Vegas. This is the first Sprint in-building coverage and capacity agreement involving a large healthcare institution in the Las Vegas market.

23 Nov 2009

Phase IIb/III clinical trial results of CINQUIL for pediatric EoE announced

Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms.

23 Nov 2009

Neurobiological Technologies declares extraordinary dividend

Neurobiological Technologies, Inc. announced today that its board of directors has declared an extraordinary dividend of $0.18 per share of common stock, which will be paid on December 9, 2009 to stockholders of record as of November 30, 2009.

23 Nov 2009

Librax AG version launched by Oceanside Pharmaceuticals

Oceanside Pharmaceuticals, part of Valeant Pharmaceuticals International, today announced that it has now launched chlordiazepoxide hydrochloride and clidinium bromide, an authorized generic (AG) version of Librax®. Oceanside has received its first orders and expects to be a significant player in the Librax® generic market.

23 Nov 2009

Receptos raises $25 million through Series A financing

Receptos, Inc., a privately held biopharmaceutical company, announced the closing of a two-tranche $25 million Series A financing. The company is focused on identifying and developing best- and first-in-class GPCR therapeutic candidates through information-driven drug discovery, including GPCR structure. Investors include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock.

23 Nov 2009

Bio-Quant to be acquired by NexMed

NexMed, Inc., a developer of products based on the NexACT® technology, today announced that it has entered into a definitive agreement to acquire Bio-Quant, Inc., a revenue generating privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.

23 Nov 2009

Augusta woman sues Fairbank Farms over E. coli infected ground beef

As news broke that more Maine residents may be infected with E. coli from Fairbank Farms ground beef, an Augusta woman severely sickened in the E. coli outbreak has filed suit against the company. The lawsuit was filed in the Maine District Court by the plaintiff’s attorneys, Bill Marler of foodborne illness law firm Marler Clark, and Peter Felmley of the Portland firm Drummond, Woodsum, & MacMahon.

23 Nov 2009

AppDetectivePro solution from Application Security awarded Certificate of Networthiness by U.S. Army

Application Security, Inc., the leading provider of database security, risk and compliance solutions (SRC) for the enterprise, today announced that its has received a Certificate of Networthiness (CoN) from the U.S. Army Network Enterprise Technology Command (NETCOM) for its AppDetectivePro™ solution. With over one hundred thousand databases protected, AppDetectivePro is the defacto standard tool for database auditing.

23 Nov 2009

MMR Information Systems to add new feature in its personal health record website

MMR Information Systems, Inc. announced today it will add a clinical trials information service to its MyMedicalRecords Personal Health Record site, www.mymedicalrecords.com.

23 Nov 2009

Lannett CEO to participate in NYSE opening bell ringing ceremony

Lannett Company, Inc. (NYSE AMEX: LCI) today announced that President and Chief Executive Officer Arthur Bedrosian will ring the opening bell at the New York Stock Exchange at 9:30 a.m. Eastern on Monday, November 23, 2009.

23 Nov 2009

Medical News

Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented

AMD LASERS announces new collaboration to continue its dental education

Acucela to present data on its ACU-4429 visual cycle modulator for dry AMD

Masimo announces the renewal of multi-year agreement by Advocate Health Care

Texas Court dismisses all claims against Merck in VIOXX-related lawsuit

Asterand extends its collaboration agreement with Bristol-Myers Squibb

AdnaTest BreastCancer Select & Detect kit now available in the Czech Republic and Slovakia

Zynx Health partners with Healthcare Solutions Division of Keane for EHR integration

Isis Pharmaceuticals CEO's letter to shareholders

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Nevada Cancer Institute selects Sprint as its wireless communications provider at its new Las Vegas facility

Phase IIb/III clinical trial results of CINQUIL for pediatric EoE announced

Neurobiological Technologies declares extraordinary dividend

Librax AG version launched by Oceanside Pharmaceuticals

Receptos raises $25 million through Series A financing

Bio-Quant to be acquired by NexMed

Augusta woman sues Fairbank Farms over E. coli infected ground beef

AppDetectivePro solution from Application Security awarded Certificate of Networthiness by U.S. Army

MMR Information Systems to add new feature in its personal health record website

Lannett CEO to participate in NYSE opening bell ringing ceremony

How real-time off-gas analysis improves fermentation process control

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Latest News